GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (ASX:CGS) » Definitions » COGS-to-Revenue

Cogstate (ASX:CGS) COGS-to-Revenue : 0.48 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cogstate COGS-to-Revenue?

Cogstate's Cost of Goods Sold for the six months ended in Dec. 2023 was A$13.36 Mil. Its Revenue for the six months ended in Dec. 2023 was A$27.64 Mil.

Cogstate's COGS to Revenue for the six months ended in Dec. 2023 was 0.48.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cogstate's Gross Margin % for the six months ended in Dec. 2023 was 51.65%.


Cogstate COGS-to-Revenue Historical Data

The historical data trend for Cogstate's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogstate COGS-to-Revenue Chart

Cogstate Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.56 0.45 0.41 0.47

Cogstate Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.41 0.58 0.38 0.48

Cogstate COGS-to-Revenue Calculation

Cogstate's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=28.106 / 60.272
=0.47

Cogstate's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=13.361 / 27.635
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cogstate  (ASX:CGS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cogstate's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 13.361 / 27.635
=51.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Cogstate COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cogstate's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogstate (ASX:CGS) Business Description

Traded in Other Exchanges
Address
161 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the company is the sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis, and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.

Cogstate (ASX:CGS) Headlines

No Headlines